Skip to main content
    F

    Fate Therapeutics Inc (FATE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.14
    -0.14 (-10.94%)

    Market Cap: $155.74M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Fate Therapeutics Inc (FATE) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Fate Therapeutics (FATE) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Fate Therapeutics reported EPS of -$0.25, above the -$0.27 estimate. It beat the EPS estimate in 6 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    48%(19/40)
    Avg Surprise
    -1.62%
    Streak
    3 Q

    Upcoming Estimates

    Reports Feb 24, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.25
    Range-$0.27 - -$0.16
    14 analysts
    Revenue Consensus
    $850.00K
    RangeN/A
    14 analysts
    Reports May 11, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.27
    Range-$0.33 - -$0.23
    5 analysts
    EPS Revisions
    2
    1
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.28+5.6%
    60d ago-$0.28+2.9%
    30d ago-$0.28+2.9%
    7d ago-$0.28+2.9%
    Current-$0.27
    Revenue Consensus
    $671.43K
    RangeN/A
    7 analysts

    Next Report

    FATE has an expected report date of Feb 24, 2027.

    Earnings History

    Of the 40 quarters below that had an estimate, FATE beat 19, missed 18 and matched 3. The widest gap in the table came in the quarter ended Sep 30, 2020, when EPS landed 88.89% below the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.25-$0.27-$0.28 - -$0.21+7.41%BeatN/A84 up, 2 downNov 5, 2026N/A
    Jun 30, 2026-$0.25-$0.28-$0.28 - -$0.22+10.71%BeatN/A91 up, 0 downAug 13, 2026$2.08M
    Mar 31, 2026-$0.26-$0.28-$0.30 - -$0.25+7.14%BeatN/A81 up, 0 downMay 13, 2026$1.30M
    Dec 31, 2025-$0.27-$0.27-$0.29 - -$0.250.00%In lineN/A8N/AFeb 26, 2026$1.37M
    Sep 30, 2025-$0.27-$0.28-$0.37 - -$0.23+3.57%BeatN/A90 up, 1 downNov 13, 2025$1.74M
    Jun 30, 2025-$0.29-$0.34-$0.44 - -$0.27+14.71%BeatN/A114 up, 1 downAug 12, 2025$1.91M
    Mar 31, 2025-$0.32-$0.38-$0.43 - -$0.28+15.79%BeatN/A75 up, 0 downMay 13, 2025$1.63M
    Dec 31, 2024-$0.44-$0.42-$0.49 - -$0.35-3.82%MissN/A132 up, 7 downMar 5, 2025$1.86M
    Sep 30, 2024-$0.40-$0.41-$0.66 - -$0.37+2.44%BeatN/A180 up, 0 downNov 12, 2024$3.07M
    Jun 30, 2024-$0.33-$0.45-$0.64 - -$0.40+26.67%BeatN/A180 up, 0 downAug 13, 2024$6.77M
    Mar 31, 2024-$0.47-$0.45-$0.67 - -$0.42-4.44%MissN/A181 up, 0 downMay 9, 2024$1.93M
    Dec 31, 2023-$0.45-$0.52-$0.71 - -$0.32+13.46%BeatN/A210 up, 0 downFeb 26, 2024$1.68M
    Sep 30, 2023-$0.46-$0.56-$0.76 - -$0.37+17.86%BeatN/A211 up, 0 downNov 8, 2023$1.94M
    Jun 30, 2023-$0.54-$0.58-$0.78 - -$0.34+6.90%BeatN/A210 up, 0 downAug 8, 2023$933000
    Mar 31, 2023-$0.19-$0.62-$1.06 - -$0.15+69.35%BeatN/A210 up, 0 downMay 3, 2023$58.98M
    Dec 31, 2022-$0.58-$0.86-$1.12 - -$0.56+32.56%BeatN/A241 up, 0 downFeb 28, 2023$44.36M
    Sep 30, 2022-$0.86-$0.87-$1.06 - -$0.77+1.15%BeatN/A220 up, 0 downNov 3, 2022$14.98M
    Jun 30, 2022-$0.78-$0.81-$1.00 - -$0.65+3.70%BeatN/A220 up, 0 downAug 3, 2022$18.55M
    Mar 31, 2022-$0.68-$0.74-$0.90 - -$0.63+8.11%BeatN/A190 up, 1 downMay 4, 2022$18.41M
    Dec 31, 2021-$0.72-$0.67-$0.94 - -$0.41-7.46%MissN/A19N/AFeb 28, 2022$17.07M
    Sep 30, 2021-$0.45-$0.55-$0.74 - -$0.41+18.18%BeatN/A163 up, 0 downNov 4, 2021$14.22M
    Jun 30, 2021-$0.58-$0.52-$0.60 - -$0.41-11.54%MissN/A14N/AAug 4, 2021$13.41M
    Mar 31, 2021-$0.44-$0.43-$0.52 - -$0.31-2.33%MissN/A15N/AMay 5, 2021$11.14M
    Dec 31, 2020-$0.61-$0.39-$0.43 - -$0.34-56.41%MissN/A16N/AFeb 24, 2021$15.90M
    Sep 30, 2020-$0.68-$0.36-$0.44 - -$0.31-88.89%MissN/A15N/ANov 5, 2020$7.56M
    Jun 30, 2020-$0.35-$0.29-$0.47 - $0.22-20.69%MissN/A16N/AAug 5, 2020$5.46M
    Mar 31, 2020-$0.44-$0.39-$0.45 - -$0.29-12.82%MissN/A16N/AMay 11, 2020$2.52M
    Dec 31, 2019-$0.37-$0.39-$0.48 - -$0.28+5.13%BeatN/A15N/AMar 2, 2020$2.80M
    Sep 30, 2019-$0.40-$0.37-$0.41 - -$0.30-8.11%MissN/A14N/ANov 5, 2019$2.43M
    Jun 30, 2019-$0.36-$0.31-$0.39 - -$0.18-16.13%MissN/A12N/AAug 6, 2019$2.82M
    Mar 31, 2019-$0.30-$0.23-$0.27 - -$0.17-30.43%MissN/A8N/AMay 7, 2019$2.63M
    Dec 31, 2018-$0.25-$0.24-$0.34 - -$0.10-4.17%MissN/A8N/AMar 5, 2019$1.66M
    Sep 30, 2018-$0.31-$0.28-$0.36 - -$0.10-10.71%MissN/A7N/ANov 1, 2018$1.03M
    Jun 30, 2018-$0.37-$0.32-$0.38 - -$0.18-15.63%MissN/A7N/AAug 6, 2018$1.03M
    Mar 31, 2018-$0.27-$0.22-$0.25 - -$0.17-22.73%MissN/A6N/AMay 10, 2018$1.03M
    Dec 31, 2017-$0.29-$0.24-$0.27 - -$0.21-20.83%MissN/A7N/AMar 5, 2018$1.03M
    Sep 30, 2017-$0.25-$0.25-$0.26 - -$0.240.00%In lineN/A5N/ANov 1, 2017$1.03M
    Jun 30, 2017-$0.23-$0.23-$0.27 - -$0.200.00%In lineN/A5N/AAug 14, 2017$1.03M
    Mar 31, 2017-$0.24-$0.20-$0.22 - -$0.19-20.00%MissN/A5N/AMay 15, 2017$1.03M
    Dec 31, 2016-$0.21-$0.29N/A+27.59%BeatN/AN/AN/AMar 16, 2017$1.03M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$1.15, after -$1.64 the year before. It was -$1.06 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$1.15N/A
    Dec 31, 2024-$1.64N/A
    Dec 31, 2023-$1.64N/A
    Dec 31, 2022-$2.90N/A
    Dec 31, 2021-$2.19N/A
    Dec 31, 2020-$2.08N/A
    Dec 31, 2019-$1.43N/A
    Dec 31, 2018-$1.20N/A
    Dec 31, 2017-$1.01N/A
    Dec 31, 2016-$1.06N/A

    Frequently Asked Questions About FATE

    When is Fate Therapeutics's next earnings date?

    Fate Therapeutics's next earnings report is expected for Feb 24, 2027.

    Did FATE beat earnings estimates last quarter?

    Yes. Fate Therapeutics reported EPS of -$0.25 for the quarter ended Sep 30, 2026, above the -$0.27 estimate, a 7.41% surprise.

    What EPS do analysts expect from FATE next quarter?

    The consensus EPS estimate for Fate Therapeutics for the quarter ending Dec 31, 2026 is -$0.25 from 14 analysts, with estimates from -$0.27 to -$0.16.

    How often does FATE beat earnings estimates?

    Fate Therapeutics beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +6.94%.